TCGA-49-AARO-01A-12R-A41B-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 39
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
- ANGIOGENESIS+0.400
- COAGULATION+0.380
- IL6_JAK_STAT3_SIGNALING+0.370
- ALLOGRAFT_REJECTION+0.350
- INFLAMMATORY_RESPONSE+0.330
- KRAS_SIGNALING_UP+0.320
- MYOGENESIS+0.320
- APICAL_JUNCTION+0.300
- INTERFERON_GAMMA_RESPONSE+0.290
Top 10 suppressed
- MYC_TARGETS_V1-0.650
- MYC_TARGETS_V2-0.600
- E2F_TARGETS-0.570
- G2M_CHECKPOINT-0.550
- OXIDATIVE_PHOSPHORYLATION-0.550
- PROTEIN_SECRETION-0.550
- UNFOLDED_PROTEIN_RESPONSE-0.510
- MTORC1_SIGNALING-0.490
- DNA_REPAIR-0.450
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013478 | — | cohortMD2 | 0.949 |
| 2 | TCGA-DK-AA6S-01A-21R-A39I-07 | — | — | 0.940 |
| 3 | SRR8392886 | — | cohortA1 | 0.939 |
| 4 | SRR26320079 | — | — | 0.932 |
| 5 | TCGA-99-AA5R-01A-11R-A39D-07 | — | cohortA1 | 0.932 |
| 6 | TCGA-98-A53H-01A-12R-A262-07 | — | cohortA1 | 0.931 |
| 7 | BS_2SHWPB5P | ganglioneuroblastoma | — | 0.929 |
| 8 | SRR1362464 | GTEX | — | 0.929 |
| 9 | MNG809 | — | — | 0.928 |
| 10 | SRR1429957 | GTEX | — | 0.927 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.430 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| COAGULATION | 0.380 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.330 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| MYOGENESIS | 0.320 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.270 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.240 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.220 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| HYPOXIA | 0.150 | Idelalisib | — uncovered |
| APOPTOSIS | 0.090 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.080 | Inavolisib | — uncovered |